ERBB2 and breast cancer: Additionally, the upregulation of CMTM6 causes trastuzumab resistance and promotes breast cancer proliferation by increasing HER2 expression through the manipulation of downstream MAPK and PI3K/AKT/mTOR signaling pathways [193].